Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.

Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study.

Benefits of metformin outweigh risks among young people with overweight or obesity and treated with second-gen antipsychotics.

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

Three new studies shed light on some common questions about atrial fibrillation: whether your morning coffee matters, whether ...

A detailed look at how Laellium’s gelatin trick for weight loss uses gelatin and six research-supported ingredients to ...

The META-AF trial found fewer recurrences of atrial arrhythmias, a benefit unexplained by weight loss or glycemic control.

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today ...

This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss ...

Metformin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. Weight loss is recognized as a side effect of metformin, and many people who treat their ...